angiogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-03. Anything still debated is marked as such rather than presented as settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Octodrine, also known as dimethylhexylamine (DMHA) and sold under the brand name Vaporpac among others, is a sympathomimetic and stimulant medication that was formerly used in the treatment of hypotension (low blood pressure). It has been studied in a dozen animal studies from the 1940s through the 1970s. These studies found that octodrine can increase blood pressure and cardiac output in animals. The drug was previously approved for use by the Food and Drug Administration (FDA) as an inhalant (i.e., Vaporpac and Tickle Tackle Inhaler) and in Germany as an oral medication as part of a multi-component medication (i.e., Ambredin and Ordinal), but is no longer available. DMHA has also been found as an adulterant in preworkout products and is also sold online as a designer drug. The presence of a reductive amination byproduct in seized samples confirms the drug is fully synthetic in origin. In the United States, the FDA considers DMHA to be an unsafe ingredient in dietary supplements. In 2019, the FDA issued nine warning letters to US manufacturers of dietary supplements containing DMHA as an unsafe food additive, deeming such products to be adulterated and illegal for marketing.
A 2017 literature review indicated there are numerous potential carcinogens of colorectal tissue in red meat, particularly those in processed red meat products, such as N-nitroso compounds, polycyclic aromatic hydrocarbons (PAHs), and heterocyclic amines (HCAs). Cooking meat with "high-temperature methods, such as pan frying or grilling directly over an open flame", also causes formation of PAHs and HCAs.
JRT, also known as isotryptamine-LSD, is a serotonin receptor modulator, psychoplastogen, and serotonergic psychedelic related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the embedded tryptamine structure within the ergoline ring system of LSD has been replaced with an isotryptamine structure. The drug acts as a non-selective serotonin receptor modulator, including as a partial agonist of the serotonin 5-HT2A receptor and as an agonist or antagonist of various other serotonin receptors. The drug has psychedelic-like, psychoplastogenic, antipsychotic-like, antidepressant-like, and pro-cognitive effects in animals and preclinical studies, whilst lacking apparent pro-psychotic-like effects. It has significant but reduced psychedelic-like effects compared to LSD in animals. The drug is a racemic mixture of (+)- and (–)- enantiomers, with (+)-JRT being the active and employed form. JRT was first described in the scientific literature by 2022 and was described in greater detail in 2025. It was developed by David E. Olson and colleagues in association with Delix Therapeutics. The drug is being investigated as a possible treatment for schizophrenia.
Neal Benowitz, a professor of medicine at UC San Francisco who is an expert on ephedrine and other stimulants, agreed that "These [levels] are what you'd see from someone taking cold or allergy medicines and are unlikely to have any effect on performance." Following Exum's revelations the IAAF acknowledged that at the 1988 Olympic Trials the USOC indeed followed the correct procedures in dealing with eight positive findings for ephedrine and ephedrine-related compounds in low concentration. The federation also reviewed in 1988 the relevant documents with the athletes' names undisclosed and stated that "the medical committee felt satisfied, however, on the basis of the information received that the cases had been properly concluded by the USOC as 'negative cases' in accordance with the rules and regulations in place at the time and no further action was taken".
In the 1960s, Ajinomoto began to diversify its production by securing alliances with international food companies, including the Kellogg Company in 1962, CPC International Inc. in 1963, and Best Foods Company Ltd. in 1964. Because of these partnerships, Ajinomoto began selling Kellogg's corn flakes and Knorr soup in Japan and created its own brand of mayonnaise. During this time period, Ajinomoto modified AJI-NO-MOTO's recipe by using amino acids from sugar cane instead of soybeans, which allowed the seasoning to be produced locally in the countries it was exported to, which reduced shipping costs for the company. Domestic production first began in Thailand in 1962, followed by the Philippines (previously established in 1958), Malaysia, Peru, Indonesia, and Brazil in subsequent years. By 1979, nearly half of all AJI-NO-MOTO was being produced outside of Japan. In the 1970s, Ajinomoto diversified further by launching a flavored seasoning called HON-DASHI in 1970 and producing frozen foods in 1972. In 1973 Ajinomoto and General Foods Inc. launched Ajinomoto General Foods Inc., a joint venture between the two companies that would sell instant coffee. In 1978, Ajinomoto launched a brand of Chinese seasonings under the brand name "Cook Do". In Asian and Latin American markets, Ajinomoto created new products for consumers, while the company primarily delivered its products to processed food manufacturers in Europe and the United States. During this era, the company also expanded into other product markets.
Sources: en.wikipedia.org
In gas chromatography, the Kovats retention index (shorter Kovats index, retention index; plural retention indices) is used to convert retention times into system-independent constants. The index is named after the Hungarian-born Swiss chemist Ervin Kováts (1927–2012), who outlined the concept in the 1950s while performing research into the composition of the essential oils. The retention index of a chemical compound is retention time interpolated between adjacent n-alkanes. While retention times vary with the individual chromatographic system (e.g. with regard to column length, film thickness, diameter and inlet pressure), the derived retention indices are quite independent of these parameters and allow comparing values measured by different analytical laboratories under varying conditions and analysis times from seconds to hours. Tables of retention indices are used to identify peaks by comparing measured retention indices with the tabulated values.
== Early life and education == Goldstein grew up on Staten Island and received his B.S. degree from Wagner College in 1959 and his M.S. and Ph.D. degrees from Rutgers University, the latter in 1964. He served on the faculty of the Albert Einstein College of Medicine from 1964 to 1972, and as director of the Division of Biochemistry at the University of Texas Medical Branch in Galveston from 1972 through 1978 before accepting the chairmanship of the Department of Biochemistry and Molecular Biology at the George Washington University School of Medicine & Health Sciences, a position he held for 31 years.
=== Canada === The Mexican Army curtailed the ability of the Mexican drug cartels to move cocaine inside the U.S. and Canada, prompting an upsurge in gang violence in Vancouver in 2009, where the cocaine price has increased from $23,300 to almost $39,000 per kilo as the Canadian drug markets experienced prolonged shortages. As evidence of this pressure, the U.S. government stated the amount of cocaine seized on U.S. soil dropped by 41 percent between early 2007 and mid-2008. Since 2009, Vancouver has become the Mexican cartels' main center of operations in Canada.
==== Thermal Ionization MS ==== In thermal ionization mass spectrometry, small quantities of highly purified analyte are deposited onto a clean metal filament. Rhenium or tungsten are typically used. The sample is heated in a vacuum of the ion source by applying a current to the filaments. A portion of the analyte will be ionized by the filament and then are directed down the flight tube and separated based on mass to charge ratios. Major disadvantages include time-consuming sample preparation and inefficient analyte ionization.
== Transport == Fish is transported widely in ships, and by land and air, and much fish is traded internationally. It is traded live, fresh, frozen, cured and canned. Live, fresh and frozen fish need special care.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.